Brilliant Study: Assessing Cognition in Myeloma Patients Undergoing Transplant

Brilliant Study: Assessing Cognition in Myeloma Patients Undergoing Transplant

The overall objectives in this study are to identify patterns of cognitive impairment pre- and post-transplant, to assess the similarities of scores of the three cognitive assessments in myeloma patients who undergo autologous stem cell transplant, and to determine if patients prefer the self-assessment, Self-Administered Gerocognitive Exam (SAGE) or the healthcare applied Montreal Cognitive Assessment (MoCA) assessment.

The overall objectives in this study are to identify patterns of cognitive impairment pre- and post-transplant, to assess the similarities of scores of the three cognitive assessments in myeloma patients who undergo autologous stem cell transplant, and to determine if patients prefer the self-assessment, Self-Administered Gerocognitive Exam (SAGE) or the healthcare applied Montreal Cognitive Assessment (MoCA) assessment.

Inclusion Criteria:

• Patients with multiple myeloma
• Patients who will undergo pre-transplant evaluation with intentions to proceed to autologous stem cell transplant after stem cell collection.
• Patients willing and able to understand and sign an informed consent form
• Patients 18 yrs of age or older

Exclusion Criteria:

• Patients with unstable psychiatric illness within the past 3 months of study enrollment.
• Patients who are considered unable to perform study evaluations at the investigator's discretion.
• Patients who are unable to read. (If patients require reading glasses, they must be worn at time of test.)
• Patients who do not proceed to stem cell transplant within 60 days of stem cell collection will be excluded from study.
• Patients who receive more than one cycle of chemotherapy between the time of stem cell collection and transplant will be excluded from study.